Evaluation of Failure Patterns Using Trimodality in Non-Small Cell Lung Cancer

BACKGROUND: The effectiveness of trimodality therapy in NSCLC has been controversial. METHODS: Ninety-two patients with stage III NSCLC were analyzed retrospectively based on treatment given. Overall survival (OS) and patterns of failure were examined in patients treated with chemoradiation alone (G...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Shilpen, Pakish, Janelle, Yen, Philemon, Quang, Tony, Carr, Laurie, Wood, Douglas, Eaton, Keith, Mulligan, Michael, Martins, Renato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649704/
https://www.ncbi.nlm.nih.gov/pubmed/29147226
http://dx.doi.org/10.4021/wjon289w
Descripción
Sumario:BACKGROUND: The effectiveness of trimodality therapy in NSCLC has been controversial. METHODS: Ninety-two patients with stage III NSCLC were analyzed retrospectively based on treatment given. Overall survival (OS) and patterns of failure were examined in patients treated with chemoradiation alone (Group 1) versus neoadjuvant chemoradiation followed by surgical resection (Group 2). RESULTS: OS for 2, 3, and 5 years in Group 1 and 2 were 19.7%, 15.7%, and 4.5% versus 56.4%, 40.4%, and 32.3% (P = 0.003), respectively. Median survival for Group 1 and 2 was 11.0 and 34.0 months, respectively (P = 0.003). The recurrence rate in Group 1 was 61.8% (47 of 76) with distant non-brain involvement (48.9%). In Group 2 it was 50.0% (8 of 16) with brain (50%) involvement. CONCLUSIONS: Patients with stage IIIA and, perhaps IIIB NSCLC with a high performance status should be considered for trimodality treatment.

Ejemplares similares